Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide and Abiraterone Acetate in mCRPC With Biomarker Signature
NCT03360721Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2018
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide, Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2018; status: terminated.
02
Drugs
apalutamideAbiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03360721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03360721.